Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHPA Targets Policymakers With OTC Campaign To Undo “Negative Momentum”

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association aims at policymakers and thought leaders with a campaign to reverse the "negative momentum" that threatens the OTC industry with "death by a 1,000 cuts," President and CEO Scott Melville says.

You may also be interested in...



CHPA Quantifies OTCs’ Overall Value To Promote Expanded Access

Information from the CHPA-commissioned study could help improve policymakers’ understanding of the costs of making OTCs less available as well as the benefits of more Rx-to-OTC switches.

CHPA Quantifies OTCs’ Overall Value To Promote Expanded Access

Information from the CHPA-commissioned study could help improve policymakers’ understanding of the costs of making OTCs less available as well as the benefits of more Rx-to-OTC switches.

In Brief

Osteo Bi-Flex clears NAD claims review

Related Content

Topics

UsernamePublicRestriction

Register

PS104930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel